Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 2:1 Randomized Phase II Trial to Compare the Efficacy and Safety of Standard Chemotherapy Plus Quizartinib Versus Standard Chemotherapy Plus Placebo in Adult Patients With Newly Diagnosed FLT3 Wild-type AML

NCT04107727 is registered in ClinicalTrials.gov with PETHEMA Foundation as lead sponsor.

NCT NCT04107727
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04107727 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 2:1 Randomized Phase II Trial to Compare the Efficacy and Safety of Standard Chemotherapy Plus Quizartinib Versus Standard Chemotherapy Plus Placebo in Adult Patients With Newly Diagnosed FLT3 Wild-type AML
Lead sponsor
PETHEMA Foundation
Phase
Phase 2
Overall status
Completed
Start date
September 5, 2019
Completion date
January 24, 2025
Enrollment
273 (actual)
Sites
45

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia